BVS Stock Forecast: Bioventus, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Bioventus, Inc. hold a median 12-month price target of $16 — +61.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bioventus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Revisions (31): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BVS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +61.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Canaccord Genuity | Maintains | Buy | $19 → $18 |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Buy | $15 → $19 |
| 17 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $15 |
| 30 June 2026 | Barrington Research | Maintains | Outperform | $14 |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 22 May 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 9 Feb 2026 | Barrington Research | Initiates | Outperform | — |
| 7 July 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 17 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 17 Dec 2024 | JP Morgan | Upgrade | Neutral | — |
| 6 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 27 Sept 2024 | Craig-Hallum | Maintains | Buy | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 7 Aug 2024 | Craig-Hallum | Maintains | Buy | — |
| 8 May 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2024 | Craig-Hallum | Maintains | Buy | — |
| 7 Dec 2023 | Canaccord Genuity | Upgrade | Buy | — |
| 3 Apr 2023 | Craig-Hallum | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BVS.
This page is one stock. Monday covers all of them.
BVS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BVS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bioventus, Inc. returned +51.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BVS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 12.2×
- Price / sales
- 1.2×
- Price / book
- 2.8×
- EV / EBITDA
- 12.1×
Cheaper than 65% of US stocks
Cheaper than 62% of US stocks
Cheaper than 33% of US stocks
Cheaper than 46% of US stocks
- Revenue growth (YoY)
- 2.7%
- Earnings growth (YoY)
- 89.8%
- Gross margin
- 69.0%
- Operating margin
- 10.1%
- Net margin
- 9.8%
Higher than 34% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 63% of US stocks
Higher than 67% of US stocks
- Return on equity
- 25.8%
- Return on assets
- 5.4%
- Dividend yield
- —
Higher than 85% of US stocks
Higher than 77% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bioventus, Inc. has a market value of $676.5M and an enterprise value of $939.0M.
Revenue in the twelve months to 30 June 2026: $581.8M. The latest quarter grew 3.8% year on year.
Net income over the same four quarters: $61.5M, a 10.6% net margin.
Diluted earnings per share, trailing twelve months: $0.77.
Free cash flow in the twelve months to 30 June 2026: $94.3M.
Trailing P/E: 12.2×; forward P/E: 11.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Bioventus, Inc. employs 960 people — $606K of revenue per employee.
Data provided by Twelve Data
BVS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BVS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bioventus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BVS
What is the BVS stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Bioventus, Inc. have a median 12-month price target of $16, with estimates ranging from $15 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BVS stock a buy right now?
Of the 5 analysts covering Bioventus, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bioventus, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BVS?
As at 21 Nov 2026, Bioventus, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
Will BVS stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +61.9% from the last close, and Ticker Nerd's factor model ranks Bioventus, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BVS stock forecast for 2030?
No analyst covering Bioventus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $18 over the next 12 months.
How has BVS stock performed over the past year?
Bioventus, Inc. returned +51.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bioventus, Inc. do?
Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions.
About Bioventus, Inc.
Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions. Its current business is organized around active healing therapies, surgical solutions, and related products used in both U.S. and international markets. The company’s portfolio includes therapies such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture-healing technologies. Bioventus operates as a specialized healthcare company within the broader medical device sector, with offerings aimed at non-surgical and surgical treatment settings.
CEO Mr. Robert E. Claypoole · 960 employees · United States · https://www.bioventus.com